[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560059":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"King's College Hospital NHS Trust","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Healthy Participants",null,[12],"Drug: Dapagliflozin",{"label":14,"type":10,"description":10,"interventionNames":15},"Patients with hyperfiltration",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DRUG","Dapagliflozin","On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.",[9,14],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Kate Bramham, Doctor","CONTACT","0203 299 9000","kch-tr.research@nhs.net",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"King's College Hospital","RECRUITING","London","United Kingdom","UK",{"type":36,"coordinates":37},"Point",[38,39],-0.12574,51.50853,{"lat":39,"lon":38},[42],{"name":43,"role":25,"phone":44,"phoneExt":10,"email":45},"Pearl Dulawan","02032995658","pearldulawan@nhs.net",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":6},"King's College London","100560059","dynamic-renal-assessment-novel-methods-to-assess-kidney-functional-reserve-100560059",false,"NCT06572215","DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve","DYNAMO","Inclusion:\n\n* Patients with sickle cell nephropathy, diagnosed clinically or histologically. Sickle Cell patients will be confirmed Hb SS and eGFR (CKD-EPI) ≥ 135 ml\u002Fmin\u002F1.73m2 OR\n* Previous living kidney donation\n* Age ≥ 4No contraindication or known allergy to any trial medications.\n* Willing and able to provide written informed consent\n\nExclusion:\n\n* Aged \\< 40\n* Unable or unwilling to provide informed consent\n* Breastfeeding or pregnant women\n* Patients involved in other interventional research studies.",true,"ALL","40 Years",{"count":62,"type":63},44,"ESTIMATED","OBSERVATIONAL","This is a feasibility study to assess new, more practical ways of measuring renal reserve.",[67],"Chronic Kidney Diseases","2026-03-26",{"date":70,"type":71},"2026-04-01","ACTUAL",{"date":73,"type":71},"2023-12-14",{"date":75,"type":63},"2027-12-31",{"name":5,"class":6},1]